atorvastatin

FDA-Approved Indications:

Primary hyperlipidemia and mixed dyslipidemia:

• Reduces elevated total cholesterol, LDL-C, apolipoprotein B (ApoB), and triglycerides
• Increases HDL-C
• Used as an adjunct to diet when diet and lifestyle modification alone are insufficient

Prevention of cardiovascular events:

• Primary prevention — reduces the risk of MI, stroke, revascularization procedures, and angina in adults without clinically evident coronary heart disease but with multiple risk factors (hypertension, smoking, low HDL, family history of early CHD, age ≥45 in men / ≥55 in women)
• Secondary prevention — reduces the risk of MI, stroke, revascularization, hospitalization for heart failure, and angina in patients with clinically evident coronary heart disease (post-MI, stable angina, ACS)

Heterozygous familial hypercholesterolemia (HeFH):

• Adults and pediatric patients aged 10–17 years (postmenarchal girls only) with HeFH who have LDL-C ≥190 mg/dL or LDL-C ≥160 mg/dL with a positive family history of premature CVD or two or more other CVD risk factors

Homozygous familial hypercholesterolemia (HoFH):

• Adults and pediatric patients aged 10 years and older; used as an adjunct to other lipid-lowering treatments (LDL apheresis) or when such treatments are unavailable

Hypertriglyceridemia:

• As an adjunct to diet for patients with primary hypertriglyceridemia (Fredrickson Type IV)

Primary dysbetalipoproteinemia (Type III hyperlipoproteinemia):

• As an adjunct to diet in patients who do not respond adequately to diet

---

ACC/AHA Statin Benefit Groups (2019 Guidelines): Atorvastatin 40–80 mg is a high-intensity statin recommended as first-line therapy for:

1. Clinical ASCVD (secondary prevention) — all patients regardless of LDL-C
2. LDL-C ≥190 mg/dL (familial hypercholesterolemia)
3. Diabetes mellitus aged 40–75 with LDL-C 70–189 mg/dL
4. 10-year ASCVD risk ≥7.5% in patients aged 40–75 with LDL-C 70–189 mg/dL

Statin Intensity Classification

Atorvastatin 80 mg is the highest FDA-approved dose and provides the greatest LDL reduction. The TNT trial demonstrated that 80 mg vs. 10 mg reduced major cardiovascular events by an additional 22% in patients with stable coronary disease.

---

Dosing by Indication

---

Administration Instructions

• May be taken at any time of day, with or without food (unlike some other statins that require evening dosing)
• Swallow tablets whole; do not crush or chew
• Consistent daily timing is preferred but not critical — atorvastatin's long half-life (14 hours, active metabolites up to 20–30 hours) provides sustained enzyme inhibition regardless of timing
• If a dose is missed: take as soon as remembered unless it is almost time for the next dose; do not double doses

---

Dose Adjustments

Renal impairment: No dose adjustment required — atorvastatin is not significantly renally cleared.

Hepatic impairment: Contraindicated in active liver disease or unexplained persistent elevations of hepatic transaminases. Use with caution in patients with a history of liver disease; start at 10 mg and titrate slowly.

Drug interactions requiring dose limits:

• Clarithromycin, itraconazole, HIV protease inhibitors: limit atorvastatin to 20 mg/day
• Nelfinavir: limit to 40 mg/day
• Cyclosporine: avoid combination (if unavoidable, limit to 10 mg/day)

Atorvastatin is a competitive inhibitor of HMG-CoA reductase (3-hydroxy-3-methylglutaryl-coenzyme A reductase), the rate-limiting enzyme in the mevalonate pathway — the primary pathway for endogenous cholesterol biosynthesis in the liver.

Step-by-step mechanism:

1. HMG-CoA reductase inhibition HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate, an early and committed step in cholesterol synthesis. Atorvastatin's open-acid form binds to the enzyme's active site with ~1,000-fold higher affinity than the natural substrate HMG-CoA, competitively blocking this step and dramatically reducing hepatic cholesterol production.

2. Upregulation of hepatic LDL receptors When intracellular cholesterol falls, hepatocytes respond by upregulating LDL receptor expression on their surface (via SREBP-2 transcription factor activation). More LDL receptors means more LDL particles are cleared from the bloodstream, reducing circulating LDL-C by 37–51% (10 mg dose) to 51–60% (80 mg dose).

3. Reduction of VLDL and triglycerides By reducing hepatic cholesterol synthesis, atorvastatin also decreases VLDL production and secretion, leading to a 20–40% reduction in triglycerides — particularly useful in patients with combined hyperlipidemia.

4. Pleiotropic (non-lipid) effects Beyond LDL reduction, atorvastatin has demonstrated:

• Anti-inflammatory effects: reduces high-sensitivity CRP (hsCRP) by 20–50%, independent of LDL lowering (JUPITER-like effects)
• Endothelial function improvement: increases nitric oxide bioavailability, reducing vascular inflammation
• Plaque stabilization: reduces lipid-rich plaque vulnerability to rupture by decreasing macrophage infiltration and metalloproteinase activity
• Antithrombotic effects: modest reduction in platelet aggregation and thrombus formation

These pleiotropic effects may explain why statins reduce cardiovascular events faster (within weeks) than would be expected from LDL reduction alone.

Key clinical trial evidence:

• ASCOT-LLA (2003): Atorvastatin 10 mg vs. placebo in hypertensive patients without high cholesterol — 36% reduction in non-fatal MI and fatal CHD; trial stopped early for benefit
• TNT (2005): Atorvastatin 80 mg vs. 10 mg in stable coronary disease — 22% additional reduction in major cardiovascular events with high-intensity dosing
• CARDS (2004): Atorvastatin 10 mg vs. placebo in type 2 diabetes without prior CVD — 37% reduction in major cardiovascular events; trial stopped 2 years early
• MIRACL (2001): Atorvastatin 80 mg started within 24–96 hours of ACS — 16% reduction in recurrent ischemic events at 16 weeks

CYP3A4 Inhibitors (increase atorvastatin levels → increased myopathy risk):

Lipid-Modifying Agents (increased myopathy risk):

• Gemfibrozil: Inhibits OATP1B1 (reduces atorvastatin hepatic uptake) and CYP2C8; increases atorvastatin AUC by ~35%. Avoid combination if possible; if used together, monitor closely for myopathy
• Fenofibrate: Lower myopathy risk than gemfibrozil; combination is generally acceptable with monitoring
• Niacin ≥1 g/day: Rare cases of myopathy reported; monitor for muscle symptoms

Digoxin: Atorvastatin 80 mg increases steady-state digoxin levels by ~20% (P-gp inhibition). Monitor digoxin levels when initiating or adjusting atorvastatin dose.

Oral Contraceptives: Atorvastatin increases AUC of norethindrone by ~30% and ethinyl estradiol by ~20% (CYP3A4 competition). Consider this when selecting contraceptive doses.

Colchicine: Case reports of myopathy and rhabdomyolysis with statin + colchicine combination. Use with caution; monitor for muscle symptoms.

Antacids (aluminum/magnesium hydroxide): Reduce atorvastatin Cmax by ~35% and AUC by ~10%. Administer atorvastatin ≥2 hours before or after antacids. Clinical significance is minimal given the modest effect on AUC.

CYP3A4 Inducers (reduce atorvastatin levels → reduced efficacy): Rifampin, carbamazepine, phenytoin, St. John's Wort — may substantially reduce atorvastatin plasma levels. Monitor lipid response and consider dose adjustment.

Pregnancy — Category X (Contraindicated): Atorvastatin is contraindicated during pregnancy. Cholesterol and other products of the mevalonate pathway are essential for normal fetal development. Animal studies show fetal skeletal malformations at doses that produce maternal plasma levels similar to human therapeutic doses. If a patient becomes pregnant while taking atorvastatin, discontinue immediately and advise the patient of the potential fetal hazard. Women of childbearing potential should use effective contraception.

Lactation — Contraindicated: It is unknown whether atorvastatin is present in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, women should not breastfeed while taking atorvastatin.

Pediatric Use: FDA-approved for heterozygous familial hypercholesterolemia (HeFH) in patients aged 10–17 years (postmenarchal girls only). Starting dose: 10 mg once daily; maximum dose: 20 mg once daily. Safety and efficacy not established in prepubertal patients or in patients younger than 10 years. Liver function tests should be monitored in pediatric patients.

Geriatric Use (≥65 years): Pharmacokinetics are similar in elderly patients. However, elderly patients are at higher risk for myopathy. Use with caution, especially at the 80 mg dose. No dose adjustment is required based on age alone, but start at lower doses (10–20 mg) in frail elderly patients.

Renal Impairment: No dose adjustment required — atorvastatin is not significantly renally cleared (<2% renal excretion). Atorvastatin can be used at full doses in patients with chronic kidney disease, including those on dialysis. Note: renal impairment is a risk factor for myopathy, so monitor muscle symptoms.

Hepatic Impairment: Atorvastatin is contraindicated in active liver disease. In patients with chronic stable liver disease (e.g., compensated cirrhosis, NAFLD), use with caution at low doses (10 mg) with careful monitoring of LFTs. Plasma levels are markedly elevated in patients with hepatic impairment (Child-Pugh B: 16× increase in Cmax; Child-Pugh C: 11× increase in AUC).